CClinicalTrials.gg
CompletedNCT02891109PTIREGUpdated Sep 7, 2016

Regulatory B Cells and Chronic Immune Thrombocytopenia

An observational study in Purpura, Thrombocytopenic, Idiopathic and Regulatory B Cells, sponsored by University Hospital, Brest. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-07.

Sponsored by University Hospital, Brest · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
36
Ages
18 Years and older
Sex
All
01

Study summary

The chronic immune thrombopenia is an autoimmune disease caused by B cells. These cells produce anti platelets and megakaryocytes antibodies. Some B cells, named regulatory B cells, are known to control other cells. Their action in chronic immune thrombopenia is actually unknown.

Read the detailed description

The chronic immune thrombopenia is an autoimmune disease caused by B cells. These cells produce anti platelets and megakaryocytes antibodies. Some B cells, named regulatory B cells, are known to control other cells. Their action in chronic immune thrombopenia is actually unknown. In our cohort of chronic immune thrombopenia and controls, we realized a flow cytometry analyze of B and T cells and a co-culture to determine regulatory B cells functionality.

02

Conditions studied

  • Purpura, Thrombocytopenic, Idiopathic
  • Regulatory B Cells
03

In context

Thrombocytopenia

697 studies on the registry are indexed under Thrombocytopenia; 153 are open to participants now.

This study's enrollment of 36 is below the median of 120 across 183 observational studies indexed under Thrombocytopenia.

Browse Thrombocytopenia studies →

Lead sponsor

University Hospital, Brest is the lead sponsor of 594 studies on the registry; 135 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

patients with a Purpura, Thrombocytopenic, Idiopathic, in chronic phase (>12 months) and healthy volunteers as control residents in Brest town, France.

Inclusion criteria

  • Purpura, Thrombocytopenic, Idiopathic, chronic phase (>12 months)
  • no treatment or thrombopoietin receptor agonists

Exclusion criteria

Exclusion Criteria:

  • \< 18 years
  • Purpura, Thrombocytopenic, Idiopathic, acute phase
  • pregnancy
  • others causes of thrombopenia
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
36 participants (actual)
Patient registry
No

Groups and cohorts

  • patients group

    Adults patients with chronic immune thrombocytopenia

    Biological: Biological tests

  • control group

    Adults without immune thrombocytopenia

    Biological: Biological tests

Interventions

  • BiologicalBiological tests

    From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry

06

What researchers measure

Primary outcomes

  1. Regulatory B cells functionality

    inhibition of T cells proliferation with co-culture B and T cells

    Time frame: 1 week

Secondary outcomes

  1. Cytometry immunophenotyping of B and T cells

    characterization of B and T cells by flow cytometry

    Time frame: 1 week

07

Study locations

1 site
  • CHRU de Brest
    Brest, 29609, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02891109
Lead sponsor
University Hospital, Brest
Responsible party
Sponsor
First posted
Sep 7, 2016
Start date
Jan 2015
Primary completion
Sep 2015
Completion
Sep 2015
Last update
Sep 7, 2016

Study contacts

Christophe Jamin, PhD
principal investigator · CHRU de Brest
Lenaig Le Clech, MD
principal investigator · CHRU Brest
Brigitte Pan-Petesh, MD
principal investigator · CHRU Brest

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion